New antibody takes aim at Hard-to-Treat cancers
NCT ID NCT07584954
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety and find the right dose, while also looking at whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IUAb190708, a cytotoxic antibody targeting PD-L1
What this could lead to
If it works, this could lead to a new treatment option for people with advanced solid tumors that haven't responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 90 participants, so the drug may not be effective or could have unexpected side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anyang tumor hospital
RECRUITINGAnyang, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Shanghai cancer center
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Pulmonary hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Xinhua hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••